

Voting Results of 2018 Annual General Meeting

LONDON, 18 May 2018 – Hikma Pharmaceuticals PLC (the “**Company**”) announces its Annual General Meeting (“**AGM**”), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.

As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2017 report and accounts	196,394,230	99.96	72,200	0.04	196,466,430	245,708
2. To approve a final dividend of 23 cents per share	196,485,553	99.89	225,796	0.11	196,711,349	788
3. To re-appoint PricewaterhouseCoopers LLP as auditors	196,099,742	99.69	610,679	0.31	196,710,421	1,717
4. To authorise the Audit Committee to determine the auditors' remuneration	196,703,625	100.00	5,721	0.00	196,709,346	2,792
5. To elect Soggi Olafsson as a director	195,815,999	99.55	894,642	0.45	196,710,641	1,497
6. To re-elect Said Darwazah as a director	190,417,700	96.80	6,298,814	3.20	196,716,514	1,622
7. To re-elect Mazen Darwazah as a director	193,925,828	98.58	2,783,900	1.42	196,709,728	2,410
8. To re-elect Robert Pickering as a director	190,879,517	98.02	3,848,509	1.98	194,728,026	1,984,111
9. To re-elect Ali Al-Husry as a director	195,245,623	99.26	1,464,293	0.74	196,709,916	2,222
10. To re-elect Patrick Butler as a director	193,317,043	98.28	3,393,072	1.72	196,710,115	2,022
11. To re-elect Dr. Jochen Gann as a director	195,107,616	99.19	1,602,499	0.81	196,710,115	2,022

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
12. To re-elect John Castellani as a director	193,529,031	98.38	3,180,885	1.62	196,709,916	2,222
13. To re-elect Dr. Pamela Kirby as a director	190,289,183	96.74	6,421,682	3.26	196,710,865	1,272
14. To re-elect Nina Henderson as a director	192,848,157	98.04	3,862,508	1.96	196,710,665	1,472
15. To approve the remuneration report for the year ended 31 December 2017	169,750,519	86.36	26,815,358	13.64	196,565,877	146,261
16. To approve and adopt the 2018 Management Incentive Plan	195,620,834	99.45	1,088,481	0.55	196,709,315	2,822
17. Authority to allot shares	166,598,638	84.69	30,112,333	15.31	196,710,971	1,167
18. To dis-apply pre-emption rights for general purposes	196,660,802	99.97	50,469	0.03	196,711,271	867
19. To dis-apply pre-emption rights for an acquisition or other capital investment	195,530,359	99.40	1,179,711	0.60	196,710,070	2,067
20. To authorise the Company to purchase its own shares	195,989,881	99.68	621,703	0.32	196,611,584	100,553
21. To authorise the Company to hold general meetings on no less than 14 clear days' notice	187,831,722	95.49	8,878,028	4.51	196,709,750	2,388

Declaration of final dividend

The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.3521 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to \$1.41.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs

+44 20 7399 2670

Company Secretary

Susan Ringdal

+44 20 7399 2670

VP for Investor Relations and Strategy

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

LEI: 549300BNS685UXH4JI75